Amitkumar Mehta, MD, MBA, associate professor of medicine and director of the lymphoma and chimeric antigen receptor (CAR) T-cell therapy programs, University of Alabama at Birmingham, highlights the need for novel therapy approaches for patients with high-risk mantle cell lymphoma (MCL).
Amitkumar Mehta, MD, MBA, board-certified hematologist and associate professor of medicine and director of the lymphoma and chimeric antigen receptor (CAR) T-cell therapy programs, University of Alabama at Birmingham, highlights the findings from his research paper, "Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma," and the need for novel therapy approaches for patients with high-risk mantle cell lymphoma.
Transcript
Can you provide an overview of your study on patient outcomes for blastoid and pleomorphic variants of mantle cell lymphoma?
Mantle cell lymphoma is a very rare lymphoma. Over a period of years now, we have realized that mantle cell lymphoma, you can clearly put in 3 buckets: One is low-grade mantle, the other one is very high-grade mantle. And when I say very high-grade, that is a specific characteristic on that blastoid variant, pleomorphic variant, or TP53 variant. The idea of that study is to look [at] how those patients fare in a real-world setting with the treatment, standard of care, that they received. It was not a surprising outcome because these patients do not do well.
This is kind of a benchmark. So, if you have high-risk patients who are not doing well with a conventional therapy, what it tells you is, if this is the benchmark, what the new treatments are doing in that setting—how the BTK inhibitors are working in that setting, how a noncovalent BTK inhibitor will work in that setting, or how CAR T will work in those patients. And we know that all of those have worked better than conventional chemotherapy in pleomorphic, blastoid, and TP53-altered mantle cell lymphoma.
So the bigger question with this kind of study [that] comes up is whether we can move these therapies up front in an earlier phase rather than waiting and using the therapies which are not very active. So, there was no surprise, but it was a good benchmark with a large data set to kind of look at it and say, yes, we will need more different approaches to deal with this high-risk mantle cell lymphoma.
Shelly Lanning on How Employers Can Reduce Costs by Bridging Gaps in Women's Health Care
May 3rd 2024In a presentation at the Greater Philadelphia Business Coalition on Health Women’s Health Summit, Shelly Lanning, cofounder and president of Visana Health, addressed the need for comprehensive approaches in women’s health care and their coverage options.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen